- The healthcare sector has gained immense limelight after the COVID-19 pandemic and a significant amount of developments have been observed in the sector.
- The Healthcare sector has shown the immense potential to double the returns of the investors.
- The top performing ASX healthcare stocks are – AWC, IMU, PTX, EMD, and ACR.
A significant number of developments have been observed in the healthcare sector after the COVID-19 pandemic. The demand for medical care and home care spiked along with the development in novel treatment technologies and medicines. This demonstrates that the Healthcare sector has immense potential to double the returns of the investors.
On that note, let’s look at the healthcare stocks that have provided extraordinary returns of investors within one year.
RELATED ARTICLE: Five ASX-listed medical device stocks for year 2022
Source: ASX, Analytics: Kalkine Media
*IMU and PTX are sponsored clients.
Actinogen Medical (ASX: ACW)
Actinogen Medical (ASX: ACW) is a biotechnology company that is engaged in developing therapies for neurological diseases. Actinogen has given year to date return of 423.81%. The returns are driven by the following achievements:
- The company received RPDD (Rare Paediatric Disease Designation) from US FDA for Xanamem in Fragile X syndrome.
- High levels of Target occupancy have been witnessed in the brain for Xanamem daily dose of 5mg to 30mg.
- XanaMIA Phase 2 Study has been commenced for Alzheimer’s disease.
- AU$10 million has been secured for funding clinical trials.
- The intellectual property portfolio will be strengthened as the company filed two patents.
In 2022 and 2023, investors will be updated with series of trial results.
As on 20 October 2021, ACW shares closed the day at AU$2.160, with a market capitalisation of AU$6.47 billion.
Imugene Ltd (ASX: IMU)*
Australian biotech company, Imugene Limited (ASX: IMU) is engaged in the development of a range of novel and new immunotherapies, targeting cancer patients and eradicating tumours. Imugene stocsk has generated year to date return of 350%. The major events that took place in 2021 are:
- The company has made significant investments in three technology platforms namely, V-cell activating immunotherapies, onCARlytics and Oncolytic virotherapy.
- onCARlytics gained a license in May 2021 from the City of Hope.
- Imugene entered into a strategic partnership with Celularity in August 2021.
- In September 2021, Imugene entered the S&P/ASX 300 index.
As on 20 October 2021, IMU shares closed the day at AU$0.450, with a market capitalisation of AU$2.47 billion.
Prescient Therapeutics Ltd (ASX: PTX)*
Prescient Therapeutics (ASX: PTX) is an oncology company that develops medicines for cancer patients as per their needs and also includes cellular and targeted therapies. The company shares generated return of 258.21%. Prescient’s receptor platform – OmniCAR has driven the company’s returns as it is efficient in addressing the issues created by present generation CAR-T. Currently, there are 3 OmniCAR programs that present vast opportunities,
- CD33/CLL-1 for AML
- HER2+ solid tumours
- HER2/EGFRviii for GBM
As on 20 October 2021, PTX shares closed the day at AU$0.230, with a market capitalisation of AU$154.70 million.
Image source: © Ipopba | Megapixl.com
Emyria Limited (ASX: EMD)
Emyria Limited (ASX: EMD) develops clinical drugs with the help of data that focuses on improving patient care and enhancing treatment development. Emyria shares provided year to date return of 150% by making patients a part of the research and innovation. The focus of the company has been to work along with the regulators and secure approval for the products.
On 12 May 2021, the company announced that it has been able to gain TGA approval for remote digital health monitoring technology – Software as a Medical Device. Also, the company is working to register cannabis drug products. Moreover, the company has raised AU$8.4 million and the funds will be used in ensuring steady growth through continuous research, drug development programs and clinical services.
As on 20 October 2021, EMD shares closed the day at AU$0.240, with a market capitalisation of AU$58.44 million.
Anteris Technologies Ltd (ASX: AVR)
Anteris Technologies Ltd (ASX: AVR) aims at delivering durable and superiors’ heart-related solutions to its customers through better science and design. The company invests in next-generation technologies that can change the life of patients. On year to date basis, the company shares generated return of 140%. The major events that took place within a year are as follows:
On 6 January 2020, the company announced that it has gained funding of AU$20 million and it would run the AVR project, which includes DurAVRTM, and AVR’s 3D single-aortic development.AU$1.1 million has been raised in December 2020 to develop 3D heart Valves.
As on 20 October 2021, AVR shares closed the day at AU$9.00, with a market capitalisation of AU$72.54million.
*IMU and PTX are sponsored clients.